Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Share-based Compensation: 2015-2025

Historic Share-based Compensation for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $2.6 million.

  • Cartesian Therapeutics' Share-based Compensation rose 52.80% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 45.70%. This contributed to the annual value of $6.6 million for FY2024, which is 70.78% down from last year.
  • Cartesian Therapeutics' Share-based Compensation amounted to $2.6 million in Q3 2025, which was down 21.01% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Share-based Compensation ranged from a high of $14.1 million in Q4 2023 and a low of $1.4 million during Q1 2024.
  • Its 3-year average for Share-based Compensation is $3.4 million, with a median of $2.3 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 521.44% in 2023, then crashed by 86.81% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Share-based Compensation (Quarterly) stood at $2.3 million in 2021, then increased by 1.02% to $2.3 million in 2022, then soared by 521.44% to $14.1 million in 2023, then slumped by 86.81% to $1.9 million in 2024, then skyrocketed by 52.80% to $2.6 million in 2025.
  • Its Share-based Compensation was $2.6 million in Q3 2025, compared to $3.3 million in Q2 2025 and $2.5 million in Q1 2025.